ArticleInfection2026
Impact of colonisation with multidrug-resistant gram-negative bacteria in a low endemicity setting: a population-based observational study.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe health impact of multidrug-resistant gram-negative bacilli (MDR-GNB) colonisation in low-endemic settings remains insufficiently characterised. We aimed to evaluate mortality and healthcare utilisation associated with MDR-GNB colonisation in a Swedish population identified through targeted screening following universal risk assessment.
methodsAll patients screened for MDR-GNB in Skåne, Sweden, between 2013 and 2022, were included, with one year of follow-up. Data on mortality (primary outcome), and secondary outcomes, including emergency department (ED) visits and hospital admissions, outpatient visits and antibiotic prescriptions, were extracted from health records. Logistic regression and Cox proportional hazards models were applied to compare patients with and without MDR-GNB colonisation, with odds ratio (OR) and hazard ratios (HR) quantifying associations.
resultsAmong 12,901 screened patients, 2,485 (19%) had colonisation with extended-spectrum β-lactamase-producing Enterobacterales, 83 (0.6%) with carbapenemase-producing Enterobacterales, 50 (0.4%) with carbapenem-resistant Acinetobacter spp. and 21 (0.2%) with carbapenem-resistant Pseudomonas aeruginosa. The overall one-year mortality was 6.6%, with no association between MDR-GNB colonisation and mortality (HR 0.96, 95% CI 0.80-1.14). MDR-GNB colonisation was, however, associated with increased risk of ED visits and hospital admissions, longer hospital stays, ICU-admissions, increased use of ambulatory and primary care, and higher antibiotic prescribing. These associations were most pronounced within the first three months post-screening and declined thereafter.
conclusionsAlthough MDR-GNB colonisation did not increase one-year mortality risk, patients with colonisation experienced significantly increased healthcare use. Further research is warranted to optimise patient outcomes, including preventive measures, and healthcare resource utilisation in this population.
Indexed as
Identifiers
42455265What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.